Castle Bioscience, Inc. to sponsor Biomarker Lunch Symposium Session at Cancer Metastasis through the Lymphovascular System: Biology & Treatment, 7th International Symposium in San Francisco.

Gold Rush Ballroom April 20, 2017 12:35 pm – 1:45 pm

Session Chair: Jonathan Zager, MD

Biomarker Topic & Speakers TBD, Box Lunches will be provided.

Castle Biosciences, Inc. is a provider of molecular diagnostics to improve cancer treatment decisions. The DecisionDx™-Melanoma test assesses a melanoma patient’s unique tumor biology and resulting metastatic risk to aid treatment planning and optimize patient outcomes (; Based near Houston TX with CAP-accredited, CLIA-certified laboratory facilities in Phoenix AZ